MENU

Elizabeth Plimack, MD, MS

Betsy Plimack, MD, MS

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

About

Chief, Division of Genitourinary Medical Oncology

Professor, Department of Hematology/Oncology

Director, Genitourinary Clinical Research 

Kidney, Bladder, and Prostate Cancer TRDG Member

NCCN, Bladder/Penile Cancers Panel Member

NCCN, Kidney Cancer Panel Member

NCCN, Prostate Cancer Panel Member

Research Program

Key Awards

Philadelphia Magazine Top Docs 2019
Medical Oncology

Treatment Philosophy

With a diagnosis of cancer comes uncertainty and fear for many patients. As a medical oncologist, my first job is to help each patient understand his or her diagnosis. With that understanding, together we can design the best plan of action. At Fox Chase, each patient has the benefit of an interdisciplinary team working together to ensure the highest quality care. This interdisciplinary approach is crucial in determining and implementing the best treatment plan.

I specialize in the treatment of kidney, bladder, prostate and testicular cancer, and my clinical practice is focused on these diseases. By concentrating exclusively on genitourinary malignancies I am able to offer expert knowledge as well as access to both standard treatments and emerging therapies in the form of clinical trials. The pace of scientific discovery has accelerated in recent decades, and fortunately we have seen these discoveries translate into meaningful improvements in cancer treatments.

As part of the genitourinary group here at Fox Chase, I am proud to be a part of a team of distinguished researchers who have pioneered many of these new treatments. My particular research efforts focus on the development of new therapies for bladder and kidney cancer.

Education and Training

Educational Background

  • Chief Fellow, Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
  • Intern and Resident, Internal Medicine, New York University Medical Center / Bellevue Hospital, NY
  • MS, Patient-Based Biologic Research, University of Texas Graduate School of Biomedical Sciences, 2008
  • MD with Honors in Pathology, New York University School of Medicine, 2002

Memberships

  • National Comprehensive Cancer Network (NCCN)
    • Bladder/Penile Cancers Panel
    • Kidney/Testicular Cancers Panel
    • Prostate Cancer Panel
  • American Society of Clinical Oncology

Honors & Awards

  • Best Doctors in America® , 2019-2020, Medical Oncology and Hematology
  • Philadelphia Magazine Top Doctors, 2017-19
  • America's Top Doctors®2017
  • Leadership Forum Excellence Award, Fox Chase Cancer Center, 2012
  • Humanitas Award, Division of Cancer Medicine Hematology/Oncology Fellowship, MD Anderson Cancer Center, 2008
  • Award for Achievement in Clinical Investigation, Division of Cancer Medicine, MD Anderson Cancer Center, 2008
  • Research Forum, MD Anderson Cancer Center, 2008
  • Honorable Mention, First Annual Hematology/Oncology Fellowship Program, 2008
  • ASCO Foundation Merit Award, ASCO Genitourinary Cancers Symposium, 2008
Patient Stories

Stephen McNamara

Pancreatic Cancer;  Prostate Cancer

Stephen McNamara

Pancreatic Cancer;  Prostate Cancer

Raised with 12 siblings in Ireland, Stephen McNamara enjoyed his childhood and his country. However, in 1949, when the opportunity presented itself to come to America, he acted on it. Mary, a nursing student whom he met in England, followed her heart and came to America to marry Stephen. They settled in the Philadelphia area and raised five children. During this time, Stephen was drafted and served stateside during the Korean War. Not long after, he became a citizen of the United States. "I just fell in love with America," shares Stephen.

Paul Cervone

Bladder Cancer

Paul Cervone

Bladder Cancer

Paul Cervone was diagnosed with bladder cancer around the time he turned 50. He sought treatment at Fox Chase Cancer Center, and underwent both radiation and surgical procedures, under the care of Dr. Richard Greenberg and Dr. Elizabeth Plimack. After a long journey, with more than one recurrence, Paul has now been cancer free since 2011. "I have seen the level of care some cancer patients have received at other hospitals, and I have found them to not meet the treatment I received at Fox Chase," he said. "I have recommended Fox Chase to friends and will continue to do so. The Fox Chase team not only treated my cancers but also extended my life."

Pages

  • 1
  • 2
  • 3
  • of
  • 3
Research Profile

Research Program

Research Interests

  • Biomarkers predictive of response to neoadjuvant cisplatin based chemotherapy in bladder cancer
  • Refining neoadjuvant chemotherapy regimens for bladder cancer
  • Developmental Therapeutics – early stage clinical trials of novel agents
  • Immunotherapy in GU Malignancies
Publications

Selected Publications

Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U, Ladoire S, Theodore C, Agarwal N, Yu EY, Niegisch G, Sternberg CN, Srinivas S, Vaishampayan U, Necchi A, Liontos M, Rosenberg JE, Powles T, Bellmunt J, Galsky MD. The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. The oncologist, 2019.

Changa NM, Xie WL, Bilen MA, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncology, 20(4):581-90, 2019.

Rouvinov K, Plimack ER, Zibelman M, Ghatalia P, Geynisman DM. Update on perioperative systemic therapy for urothelial carcinoma. Clinical advances in hematology & oncology : H&O, 17(3):176-83, 2019.

Voss MH, Bhatt RS, Vogelzang NJ, Fishman M, Alter RS, Rini BI, Beck JT, Joshi M, Hauke R, Atkins MB, Burgess E, Logan TF, Shaffer D, Parikh R, Moazzam N, Zhang X, Glasser C, Sherman ML, Plimack ER. A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. Cancer, 2019.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ. Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Journal for immunotherapy of cancer, 7(1):73, 2019. PMC6416882

He AR, Cohen RB, Denlinger CS, Sama A, Birnbaum A, Hwang J, Sato T, Lewis N, Mynderse M, Niland M, Giles J, Wallin J, Moser B, Zhang W, Walgren R, Plimack ER. First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. The oncologist, 2019.

Martinez Chanza N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. The Lancet Oncology, 2019.

Godwin JL, Hoffman-Censits J, Plimack E. Recent developments in the treatment of advanced bladder cancer. Urologic oncology, 36(3):109-14, 2018. PubMed

Geynisman DM, Abbosh PH, Plimack ER, Zibelman M. Chemoimmunotherapy in Metastatic Urothelial Carcinoma. Eur Urol, 2018. 

Additional Publications

MyNCBI

Ratings

100 PATIENT SATISFACTION REVIEWS

Our Patient Satisfaction Rating is an average of all responses to care provider related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more.

OVERALL RATING

4.9 / 5.0

RATINGS BREAKDOWN

  • 4.8
  • 4.9
  • 4.9
  • 4.8
  • 4.9

24 PATIENT COMMENTS

  • 5.0
    September 27, 2019
    The very best of everything.
  • 5.0
    September 05, 2019
    Everything is very good!!
  • 5.0
    August 12, 2019
    I have been a patient of Dr. Plimack & Dr. [...], together they saved my life! (Now 10 years.) Stage - 4 bladder ca.
  • 5.0
    August 06, 2019
    Dr. Plimack is excellent as well as her staff.
  • 5.0
    July 23, 2019
    Dr Plimlick is awesome
  • 4.5
    July 07, 2019
    Experience was fine [...]
  • 5.0
    July 06, 2019
    Dr. Plimack and her team are wonderful.
  • 5.0
    May 27, 2019
    I received very good care!
  • 5.0
    May 27, 2019
    excellent
  • 5.0
    May 20, 2019
    Am so grateful with all the staff and specialty with Dr. Plimack. They are so great - A good human. God bless them all.
  • 5.0
    May 19, 2019
    Very good.
  • 4.5
    May 19, 2019
    Good.
  • 5.0
    May 07, 2019
    Cancer is very devastating, while a visit can be very scary, I always feel very at ease when I leave.
  • 5.0
    April 16, 2019
    Dr. Plimack is excellent [...].
  • 5.0
    March 18, 2019
    Great experience with Dr. Plimack and her staff! Next apt. August.
  • 5.0
    March 17, 2019
    MY Experience Has Been Excellent.
  • 5.0
    March 16, 2019
    always receive exceptional care !
  • 5.0
    March 13, 2019
    I would suggest if doctor is delayed that the nurse let the patient know. But Dr. Plimack is worth waiting for.
  • 3.5
    March 13, 2019
    provider seemed rushed; reviewed summaries but did not know the details in the report and some incorrect assumptions were made. However, the information did not change the diagnosis.
  • 5.0
    March 13, 2019
    good
LOAD MORE

Connect with Fox Chase